A Randomized Clinical Trial of Using Niosomal Zinc Sulfate Plus Cryotherapy in Comparison With Placebo Along With Cryotherapy in Treatment of Common Wart
A Randomized Clinical Trial of Using Niosomal Zinc Sulfate Plus Cryotherapy in Comparison With Placebo Along With Cryotherapy in Treatment of Common Wart
عنوان فارسی :
A Randomized Clinical Trial of Using Niosomal Zinc Sulfate Plus Cryotherapy in Comparison With Placebo Along With Cryotherapy in Treatment of Common Wart
عنوان انگلیسی :
A Randomized Clinical Trial of Using Niosomal Zinc Sulfate Plus Cryotherapy in Comparison With Placebo Along With Cryotherapy in Treatment of Common Wart
چکیده انگلیسی:
Background: There are different treatment modalities for common warts and all of them have side effects. Niosomal drug delivery systems have increased efficacy by enhanced transport of therapeutic agents through stratum corneum with decreased side effects. In this study, we assessed the efficacy of combined 2% niosomal zinc sulfate cream plus cryotherapy compared with combination of placebo plus cryotherapy. Methods: Sixty patients with verruca vulgaris enrolled in this randomized clinical trial study. Patients were divided in 2 groups. Group A received 2% niosomal zinc sulfate cream and group B received placebo twice a day. Also, patients in both groups were treated with cryotherapy (liquid nitrogen) every other week. Treatment protocols continued for a maximum of 3 months or until total clearance of the lesions. Results: Mean number of the sessions for complete remission was 4.5±1.38 in group A and 5.36±0.88 in group B and the difference between the two groups was statistically significant. Complete remission was observed in 60% in group A compared with 43.3% in group B that was not statistically significant. Conclusion: Combination therapy with niosomal zinc plus cryotherapy can lead to faster and greater percentage clearance of the lesions without significant increase in adverse effects in comparison with cryotherapy plus placebo.
خبرنامه
برای ثبت نام در خبرنامه و دریافت خبرنامه ایمیل خود را وارد نمایید.
